ReviewFrontiers in immunology2026
Gut microbiota dysbiosis in rheumatoid arthritis: mechanisms linking intestinal barrier dysfunction to synovial inflammation.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rheumatoid arthritis (RA) is a chronic, systemic, multifactorial autoimmune disease characterized by persistent synovial inflammation and progressive joint destruction. Although its etiology is complex, accumulating evidence suggests that alterations in the gut microbiota may influence disease susceptibility and progression through interactions with the host immune system. Throughout this review, we discuss the gut microbiota as one component of a broader network of mechanisms contributing to RA pathogenesis rather than as the sole initiating factor. Compromised intestinal barrier integrity and microbial dysbiosis may facilitate the translocation of microbial products, promoting immune activation and loss of tolerance. These alterations have been proposed to contribute to several pathogenic mechanisms, including molecular mimicry, protein citrullination, and disruption of the Th17/Treg balance, thereby linking mucosal immune responses with synovial inflammation. Patients with RA also frequently exhibit reduced intestinal production of short-chain fatty acids (SCFAs), particularly butyrate, which is associated with decreased abundances of SCFA-producing bacteria, including
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.